Table 2.
Post-progression characteristics and clinical outcomes.
| n | % | |
|---|---|---|
| Disease progression site | ||
| Brain | 13 | 34.2 |
| Bone | 4 | 10.5 |
| Lung | 16 | 42.1 |
| Pleura | 2 | 5.3 |
| Subcutaneous nodule | 2 | 5.3 |
| Adrenal gland | 1 | 2.6 |
| Progression pattern | ||
| New lesions | 20 | 52.6 |
| Enlargement of original lesions | 18 | 47.4 |
| Local therapy when receiving PD | ||
| No | 23 | 60.5 |
| Yes | 13 | 34.2 |
| Brain radiation | 7 | 18.4 |
| Bone radiation | 3 | 7.9 |
| Subcutaneous nodule radiation | 1 | 2.6 |
| Bone cement | 1 | 2.6 |
| Temozolomide | 1 | 2.6 |
| Duration of PFS2 | ||
| 0 to <3 months | 13 | 34.2 |
| 3 to <6 months | 9 | 23.7 |
| 6 to <9 months | 3 | 7.9 |
| 9 to <12 months | 5 | 13.2 |
| ≥12 months | 8 | 21.1 |
Abbreviations used: PD: progressive disease; PFS: progression-free survival